Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease
暂无分享,去创建一个
A. Hannan | Xin-ling Du | Xiaojun Du | G. Lambert | H. Kiriazis | N. Jennings | G. Head | P. Davern | T. Pang | Yidan Su | Xin Du | Luisa La Greca
[1] M. Mattson,et al. Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington's disease , 2012, Neurobiology of Aging.
[2] C. Colwell,et al. Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington’s disease. , 2011, PLoS currents.
[3] C. Colwell,et al. Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease , 2011, Experimental Neurology.
[4] G. Head,et al. Role of the medial amygdala in mediating responses to aversive stimuli leading to hypertension , 2011, Clinical and experimental pharmacology & physiology.
[5] G. Bates,et al. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. , 2011, The Journal of clinical investigation.
[6] G. Head,et al. Cardiovascular responses to aversive and nonaversive stressors in Schlager genetically hypertensive mice. , 2010, American journal of hypertension.
[7] J. Marinus,et al. Autonomic symptoms in patients and pre‐manifest mutation carriers of Huntington’s disease , 2010, European journal of neurology.
[8] J. Coote,et al. Vagus nerve stimulation inhibits the increase in Ca2+ transient and left ventricular force caused by sympathetic nerve stimulation but has no direct effects alone – epicardial Ca2+ fluorescence studies using fura‐2 AM in the isolated innervated beating rabbit heart , 2010, Experimental physiology.
[9] T. Walther,et al. Role of Angiotensin II Type 1A Receptors in Cardiovascular Reactivity and Neuronal Activation After Aversive Stress in Mice , 2009, Hypertension.
[10] V. Silani,et al. Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.
[11] A. Dart,et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. , 2009, The American journal of pathology.
[12] P. Brundin,et al. Beyond the brain: widespread pathology in Huntington's disease , 2009, The Lancet Neurology.
[13] S. Leurgans,et al. Daytime somnolence and nocturnal sleep disturbances in Huntington disease. , 2009, Parkinsonism & related disorders.
[14] H. Pijl,et al. Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease , 2009, Journal of Neurology.
[15] A. Rego,et al. The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease , 2009, Brain Research Reviews.
[16] A. Hannan,et al. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. , 2009, Human molecular genetics.
[17] R. Leung,et al. Sleep-disordered breathing: autonomic mechanisms and arrhythmias. , 2009, Progress in cardiovascular diseases.
[18] Hongmei Li,et al. Neural Mechanisms of Paroxysmal Atrial Fibrillation and Paroxysmal Atrial Tachycardia in Ambulatory Canines , 2008, Circulation.
[19] Brian Olshansky,et al. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. , 2008, Circulation.
[20] Marcus W. Agelink,et al. Cardiovagal modulation upon postural change is altered in Huntington’s disease , 2008, European journal of neurology.
[21] J. Robbins,et al. Cardiomyocyte Expression of a Polyglutamine Preamyloid Oligomer Causes Heart Failure , 2008, Circulation.
[22] J. Rumberger. Assessment of Cardiac Function , 2008 .
[23] Robert S. Decker,et al. Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium. , 2008, American journal of physiology. Heart and circulatory physiology.
[24] G. Head,et al. Fos-Related Antigen Immunoreactivity After Acute and Chronic Angiotensin II–Induced Hypertension in the Rabbit Brain , 2007, Hypertension.
[25] Peng-Sheng Chen,et al. Autonomic nerve activity and atrial fibrillation. , 2007, Heart rhythm.
[26] Andrew D. Steele,et al. The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases , 2007, Proceedings of the National Academy of Sciences.
[27] K. Hoyt,et al. Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.
[28] M. Fishbein,et al. New Perspectives on the Role of Autonomic Nervous System in the Genesis of Arrhythmias , 2007, Journal of cardiovascular electrophysiology.
[29] R. Graham,et al. Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival. , 2006, Cardiovascular research.
[30] G. Billman. A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. , 2006, Pharmacology & therapeutics.
[31] G. Bates. History of genetic disease: The molecular genetics of Huntington disease — a history , 2005, Nature Reviews Genetics.
[32] V. Shusterman,et al. Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. , 2005, American journal of physiology. Heart and circulatory physiology.
[33] R. Barker,et al. Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease , 2005, The Journal of Neuroscience.
[34] B. Peterlin,et al. Early sympathetic hyperactivity in Huntington's disease , 2004, European journal of neurology.
[35] Geoffrey A Head,et al. Non-symmetrical double-logistic analysis of 24-h blood pressure recordings in normotensive and hypertensive rats , 2004, Journal of hypertension.
[36] A. Allen,et al. Descending vasomotor pathways from the dorsomedial hypothalamic nucleus: role of medullary raphe and RVLM. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.
[37] M. Capecchi,et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. , 2004, The American journal of pathology.
[38] L. Burger,et al. Bradycardia and second-degree AV block: an expression of the dominance of cholinergic activity in the rigid form of Huntington's disease , 2004, Journal of Neurology.
[39] A. Dart,et al. Assessment of Cardiac Function by Echocardiography in Conscious and Anesthetized Mice: Importance of the Autonomic Nervous System and Disease State , 2003, Journal of cardiovascular pharmacology.
[40] H. Przuntek,et al. Autonomic nervous system function in Huntington's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[41] G. Jennings,et al. Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing beta(2)-adrenergic receptors in the heart. , 2000, Cardiovascular research.
[42] E. Woodcock,et al. Increased collagen content reduces the risk of post-infarct cardiac rupture in mice that overexpress β2-adrenergic, receptors in the heart , 2000 .
[43] R Lazzara,et al. Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation , 2000, Circulation.
[44] J. Romano,et al. Sympathetic skin response and heart rate variability in patients with Huntington disease. , 1999, Archives of neurology.
[45] A. Dart,et al. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. , 1999, Cardiovascular research.
[46] J Ross,et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. , 1999, The Journal of clinical investigation.
[47] M. Lohse,et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[48] I. Jonsdottir,et al. Influence of voluntary exercise on hypothalamic norepinephrine. , 1998, Journal of applied physiology.
[49] G. Mitchell,et al. Measurement of heart rate and Q-T interval in the conscious mouse. , 1998, American journal of physiology. Heart and circulatory physiology.
[50] S. W. Davies,et al. Transgenic models of Huntington's disease. , 1999, Human molecular genetics.
[51] S. W. Davies,et al. Transgenic models of Huntington's disease. Hum Mol Genet 6:1633-1637 , 1997 .
[52] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[53] Y. Furukawa,et al. Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs. , 1996, The American journal of physiology.
[54] A. Quyyumi,et al. Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.
[55] Y. Hirooka,et al. Use of c-fos functional mapping to identify the central baroreceptor reflex pathway: advantages and limitations. , 1995, Clinical and experimental hypertension.
[56] R. Dampney,et al. Functional organization of central pathways regulating the cardiovascular system. , 1994, Physiological reviews.
[57] G. Jennings,et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. , 1994, Journal of the American College of Cardiology.
[58] M. Kashiki,et al. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. , 1993, Circulation.
[59] I. Meredith,et al. Cardiac Sympathetic Nervous Activit in Congestive Heart Failure Evidence for Increased Neuronal Norepinephrine Release and Preserved Neuronal Uptake , 1993, Circulation.
[60] K. Fenger,et al. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. , 1992, Journal of medical genetics.
[61] P. Schwartz,et al. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. , 1992, Circulation.
[62] S. Sakamoto,et al. Chronic beta-adrenoceptor blockade prevents the development of beta-adrenergic subsensitivity in experimental right-sided congestive heart failure in dogs. , 1991, Circulation.
[63] D. Lanska,et al. Huntington's disease mortality in the United States , 1988, Neurology.
[64] J. G. van Dijk,et al. Autonomic nervous function in Huntington's disease. , 1988, Archives of neurology.
[65] A. Kadish,et al. Accentuated antagonism between beta-adrenergic and vagal effects on ventricular refractoriness in humans. , 1988, Circulation.
[66] E. Chiu,et al. Causes of death in Huntington's Disease , 1982, The Medical journal of Australia.
[67] J. Ross,et al. Assessment of Cardiac Function , 1969 .